Kurosaki et al. [19] reported a model to detect HCV patients at high risk of HCC, and found that the incidence of HCC was reduced more significantly in high- and intermediate-risk patients who achieved SVR with interferon (IFN)-based therapy than in non-SVR patients. Here, IFNA1 is linked to hepatocellular carcinoma.